Mustang Bio Terminates Material Definitive Agreement
Ticker: MBIO · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1680048
Sentiment: neutral
Topics: agreement-termination, material-definitive-agreement
TL;DR
Mustang Bio just terminated a big deal. Big changes ahead?
AI Summary
Mustang Bio, Inc. announced on February 7, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Worcester, Massachusetts, filed this Form 8-K to report this event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction, financial performance, and future operations.
Risk Assessment
Risk Level: medium — Terminating a material definitive agreement can signal underlying issues or strategic shifts that carry inherent business risks.
Key Players & Entities
- Mustang Bio, Inc. (company) — Registrant
- February 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Worcester, Massachusetts (location) — Principal Executive Offices
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the exact name or details of the material definitive agreement that was terminated.
What is the effective date of the termination?
The filing indicates the earliest event reported was on February 7, 2025, suggesting this is the effective date or the date the event occurred.
What are the reasons for the termination of the agreement?
The filing does not provide the reasons for the termination of the material definitive agreement.
Will this termination have a significant financial impact on Mustang Bio?
The filing does not disclose the specific financial impact of the termination.
Does this termination relate to any specific product or pipeline of Mustang Bio?
The filing does not provide details linking the termination to any specific product or pipeline.
Filing Stats: 1,844 words · 7 min read · ~6 pages · Grade level 16.2 · Accepted 2025-02-13 17:15:49
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MBIO Nasdaq Capital Marke
- $1.0 million — ender Agreement for a purchase price of $1.0 million (the "Purchase Price"). AbbVie also agr
- $2.0 million — ates potential savings of approximately $2.0 million in Lease-related payments and obligatio
Filing Documents
- tm256594d1_8k.htm (8-K) — 39KB
- 0001104659-25-013029.txt ( ) — 210KB
- mbio-20250207.xsd (EX-101.SCH) — 3KB
- mbio-20250207_lab.xml (EX-101.LAB) — 33KB
- mbio-20250207_pre.xml (EX-101.PRE) — 22KB
- tm256594d1_8k_htm.xml (XML) — 3KB
02
Item 1.02. Termination of a Material Definitive Agreement. The disclosures set forth in Item 1.01 of this Current Report on Form 8-K are incorporated into this Item 1.02 by reference with respect to the termination of the Lease pursuant to the Amendment. Cautionary Note Regarding Forward-looking Statements This Current Report on Form 8-K contains predictive or "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this Current Report on Form 8-K, including statements that express the Company's intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "should," "would" and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about the Company's business, industry and other conditions affecting its financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties, including the risks that any of the conditions in the Sale/Surrender Agreement, Escrow Agreement or Amendment are not satisfied and those risks and uncertainties described in the filings the Company makes with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligat
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mustang Bio, Inc. (Registrant) Date: February 13, 2025 By: /s/ Manuel Litchman, M.D. Name: Manuel Litchman, M.D. Title: President, Chief Executive Officer and Interim Chief Financial Officer